NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (IN8bio or the Company), today announced an upcoming presentation that provides an update of the ongoing Phase I clinical trial of their product candidate INB-100 at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH), which will take place virtually from December 5 to 8, 2020. INB-100 is designed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation with haploidentical donors.
The poster and accompanying narrated slide presentation is titled, First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated gamma delta T-Cells Following Haploidentical Bone Marrow Transplantation and Post-BMT Cyclophosphamide and reviews the study design and provides a brief update on enrollment and patient status.
The company reported that, as of abstract submission, three female subjects with acute leukemia had been enrolled in the INB-100 Phase 1 trial, of whom two had been dosed, and that no treatment-related adverse events had been recorded. The trial is continuing to enroll and treat patients. The abstract for the presentation can be found at https://ash.confex.com/ash/2020/webprogram/Paper142876.html.
The poster and slide presentation are jointly authored by the scientific and physician investigators from IN8bio and The University of Kansas Cancer Center (KU Cancer Center), and will be presented by the studys Principal Investigator, Dr. Joseph McGuirk, Schutte-Speas Professor of Hematology-Oncology, Division Director of Hematological Malignancies and Cellular Therapeutics and Medical Director, Blood and Marrow Transplant at KU Cancer Center.
This preliminary data report from KU Cancer Center with our allogeneic product candidate, INB-100, demonstrates the absence of significant GvHD in these initial patients, said William Ho, Chief Executive Officer of IN8bio. This suggests that gamma delta T-cells delivered as an off-the-shelf allogeneic cell therapy may be well tolerated and have significant potential to treat patients with serious and life-threatening cancers.
Dr. McGuirk, commented, Potentially curative stem cell transplants using partially matched donors -- called haploidentical transplants have greatly expanded access to stem cell transplantation. The infusion of donor-derived gamma delta T-cells from the stem cell donor, offers the hope of diminishing this risk of relapse and curing more patients.
About IN8bioIN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bios technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. For more information about the Company and its programs, visit http://www.IN8bio.com.
Forward Looking StatementsCertain statements herein concerning the Companys future expectations, plans and prospects, including without limitation, the Companys current expectations regarding the curative potential of its product candidates, constitute forward-looking statements. The use of words such as may, might, will, should, expect, plan, anticipate, believe, estimate, project, intend, future, potential, or continue, the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Companys control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Companys current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Companys reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.
Contact:IN8bio, Inc.Kate Rochlin, Ph.D.+1 646.933.5605info@IN8bio.com
Investor Contact:Julia Balanova+ 1 646.378.2936jbalanova@soleburytrout.com
Media Contact:Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, Inc.212-213-0006 ext. 315 / 364Rimai@burnsmc.com/rflamm@burnsmc.com
Go here to see the original:
IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio's Gamma Delta T-cell product...
- Human cells in a rat's brain could shed light on autism and ADHD - Kansas Public Radio - October 13th, 2022
- California is poised to phase out sales of new gas-powered cars - Kansas Public Radio - August 30th, 2022
- Doctors Transplant Kidneys to Children Without Need for Immune ... - July 11th, 2022
- The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies - Neurology Live - June 22nd, 2022
- Chemical Markers That May Unlock Future Therapeutic Uses of mRNA - Lab Manager Magazine - May 2nd, 2022
- Jayhawks shine at 2022 Capitol Graduate Research Summit | The University of Kansas - KU Today - April 19th, 2022
- Four researchers named recipients of the University Scholarly Achievement Award | The University of Kansas - KU Today - March 25th, 2022
- COVID-19 directly damages, creates scar tissue on the kidneys, study finds - WDAF FOX4 Kansas City - January 5th, 2022
- The controversy being created about the origins of the virus that causes COVID-19 - Frontline - July 6th, 2021
- Kelly lauds $21 billion state budget bill, vetoes $500,000 ... - June 6th, 2021
- [Full text] Binding of the SARS-CoV-2 Spike Protein | HMER - Dove Medical Press - April 15th, 2021
- Incysus Therapeutics Announces Name Change to IN8bio, Inc. - GlobeNewswire - August 28th, 2020
- Seeing through a forest of SCN2A gene variation - SFARI News - February 20th, 2020
- FHSU partners with Be the Match for bone marrow registry event - hays Post - February 20th, 2020
- Trial cancer treatment in Wichita - KAKE - December 2nd, 2019
- Infanticide: Live Organ Harvesting Commonplace in US Abortion Mills - Church Militant - October 17th, 2019
- Kansas Regenerative Stem Cell Seminar - Stem Cell Centers ... - September 10th, 2019
- Stem Cell Procedures | Motus Biologics of Kansas City - September 9th, 2019
- Stem Cell Therapy in Kansas City- Rejuvenate KC | Stem ... - April 26th, 2019
- Hip Stem Cell Treatment | Motus Biologics in Kansas City - January 23rd, 2019
- About Stem Cell Therapy - Kansas Regenerative Medicine - November 29th, 2018
- Stem Cell Therapy in Wichita, Kansas | Joint Pain Relief ... - October 6th, 2018
- Kansas Stem Cell Center Close To First Clinical Trial | KCUR - August 27th, 2018
- Knee Stem Cell Treatments in Kansas City | Motus Biologics - August 2nd, 2018
- Stem cells relieve chronic pain in Kansas City, MO - July 30th, 2018
- Adult Stem Cell Therapy 101, MSCTC - University of Kansas ... - July 7th, 2018
- Stem cells or Knee surgery - Kansas Regenerative Medicine - June 28th, 2018
- Future Fertility Fix? Egg-Producing Stem Cells Found in ... - October 14th, 2017
- Regenexx Kansas City | Helping your body heal itself - September 24th, 2017
- Feared Zika virus kills brain cancer stem cells, new research shows - Kansas City Star - September 8th, 2017
- Shawnee Woman Was Among First In The World To Undergo New FDA-Approved Cancer Therapy - KCUR - September 8th, 2017
- Paralyzed after pool accident, student heads back to college - Kansas City Star - August 30th, 2017
- About Us, Midwest Stem Cell Therapy Center - KUMC - August 30th, 2017
- Join Jon Kempin, LA Galaxy Foundation and Gift of Life Marrow Registry for Kick Blood Cancer on August 13 - LA Galaxy - August 12th, 2017
- Regenerative Medicine Market in the US - Forecasts, Segmentation, and Opportunity Assessment by Technavio - Business Wire (press release) - August 8th, 2017
- International Space Station's Crew Restored to Six People - Kansas City infoZine - July 30th, 2017
- Scientists build DNA from scratch to alter life's blueprint - Kansas City Star - July 30th, 2017
- Stem Cell Collection - University of Kansas Hospital - October 30th, 2016
- Stem Cell Therapy - North Kansas City Hospital, Kansas ... - October 14th, 2016
- Stem Cell Therapy | Kansas RMC - August 3rd, 2016
- Kansas to Build First US Stem Cell Research Center | CorCell - August 3rd, 2016
- Stem cell program - University of Kansas Medical Center - August 3rd, 2016
- Stem Cell Therapy for Urological Issues | Kansas RMC - July 29th, 2016
- Kansas Regenerative Medicine Center - October 19th, 2015
- Egg Stem Cells - MIT Technology Review - September 27th, 2015
- Doctors in Kansas who treat or diagnose Stem Cell Transplant - August 1st, 2015
- Stem Cells for Paralysis: First of Its Kind Study - April 7th, 2015
- Topeka retailer honored as 'business of the year' - March 7th, 2015
- Saint Lukes Mid America Heart Institute Offers Tips & Treatments For Heart Failure Awareness Week 2015 - February 10th, 2015
- Exploring Stem Cell Therapy for Cerebral Palsy | See the Seitz - December 12th, 2014
- Therapeutic potential of human induced pluripotent stem ... - November 5th, 2014
- Advisory Board, Midwest Stem Cell Therapy Center - November 2nd, 2014
- Myocardial infarction and stem cells - National Center for ... - October 31st, 2014
- Precise and programmable biological circuits - October 24th, 2014
- Stowers Researchers Reveal Molecular Competition Drives ... - September 6th, 2014
- Midwest Stem Cell Therapy Center, University of Kansas ... - September 1st, 2014
- Stem Cell History | A History of Stem Cell Research - August 23rd, 2014
- Kansas City MO Resources - Stem Cells: Get Facts on Uses ... - August 22nd, 2014